Antioxidants in Cancer
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: closed (15 December 2015) | Viewed by 64981
Special Issue Editor
Interests: prostate cancer; oxidative stress; inflammation
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Cellular redox homeostasis disorders are among the major players of neoplastic transformation and cancer progression. Thus, redox-active therapeutics can be used either for chemoprevention or for cancer therapy. Indeed, oxidative stress can damage the cells and induce DNA mutations responsible, among other causes, for neoplastic transformation. Hence, antioxidants can be used as chemopreventive drugs. On the other hand, compared to normal cells, cancer cells usually exhibit high basal levels of ROS, which are connected with a concomitant up regulation of antioxidant defense systems, which favor malignancy. Moreover, compared to normal cells, cancer cells have a lower tolerance to increased levels of ROS, thereby providing a plausible rationale for pro-oxidant interventions. This is a complicated topic, which can be investigated from a number of perspectives. Our final goal is the compilation of a Special Issue providing an integrated understanding of the rationale for the use of redox-active compounds as “cancer bullets” in the attempt to provide the professionals with effective concepts in the battle against cancer.
Thank you for your collaboration.
Prof. Dr. Alba Minelli
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- prooxidant molecules
- antioxidant compounds
- antioxidant defense
- neoplastic transformation
- cancer progression
- metastasis
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.